Lysyl oxidase is a potential biomarker of fibrosis in systemic sclerosis

Arthritis and Rheumatology

Volumn 66, Issue 3, 2014, Pages 726-730

  Rimar, Doron ^a   Rosner, Itzhak ^a   Nov, Yuval ^b   Slobodin, Gleb ^a   Rozenbaum, Michael ^a   Halasz, Katy ^a   Haj, Tharwat ^a   Jiries, Nizar ^a   Kaly, Lisa ^a   Boulman, Nina ^a   Daood, Rula ^a   Vadasz, Zahava ^a  

^a BNAI ZION MEDICAL CENTER   (Israel)

^b UNIVERSITY OF HAIFA   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; PROTEIN LYSINE 6 OXIDASE; BIOLOGICAL MARKER;

ADULT; ARTICLE; CAPILLAROSCOPY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; FIBROSIS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LABORATORY TEST; LUNG FIBROSIS; LUNG FUNCTION TEST; MALE; MIDDLE AGED; MYELOID METAPLASIA; PRIORITY JOURNAL; SCORING SYSTEM; SKIN FIBROSIS; SKINFOLD THICKNESS; SYSTEMIC SCLEROSIS; BLOOD; LUNG; PATHOPHYSIOLOGY; SKIN DISEASE;

ADULT; BIOLOGICAL MARKERS; FEMALE; FIBROSIS; HUMANS; LUNG; MALE; MIDDLE AGED; PROTEIN-LYSINE 6-OXIDASE; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; SKIN DISEASES;

EID: 84896284500     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38277     Document Type: Article

References (17)

1. Iwamoto N, Distler O. Molecular targets for therapy in systemic sclerosis. Fibrogenesis Tissue Repair 2012;5 Suppl 1:S19
2. Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5
3. Pope JE, Baron M, Bellamy N, Campbell J, Carette S, Chalmers I, et al. Variability of skin scores and clinical measurements in scleroderma. J Rheumatol 1995;22:1271-6
4. Steplewski A, Fertala A. Inhibition of collagen fibril formation. Fibrogenesis Tissue Repair 2012;5 Suppl 1:S29
5. Lopez B, Gonzalez A, Hermida N, Valencia F, de Teresa E, Diez J. Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspects. Am J Physiol Heart Circ Physiol 2010;299:H1-9
6. Chanoki M, Ishii M, Kobayashi H, Fushida H, Yashiro N, Hamada T, et al. Increased expression of lysyl oxidase in skin with scleroderma. Br J Dermatol 1995;133:710-5
7. Rajkumar VS, Howell K, Csiszar K, Denton CP, Black CM, Abraham DJ. Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res Ther 2005;7:R1113-23.
8. Tadmor T, Bejar J, Attias D, Mischenko E, Sabo E, Neufeld G, et al. The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms. Am J Hematol 2013;88:355-8
9. Vadasz Z, Kessler O, Akiri G, Gengrinovitch S, Kagan HM, Baruch Y, et al. Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2. J Hepatol2005;43:499-507
10. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90
11. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988;15:202-5
12. Cutolo M, Sulli A, Pizzorni C, Accardo S. Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol 2000;27:155-60
13. Medsger TA Jr, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W. Assessment of disease severity and prognosis. Clin Exp Rheumatol 2003;21 Suppl 29:S42-6
14. Hudson M, Steele R; Canadian Scleroderma Research Group (CSRG), Baron M. Update on indices of disease activity in systemic sclerosis. Semin Arthritis Rheum 2007;37:93-8
15. Bhattacharyya S, Wei J, Varga J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 2011;8:42-54
16. Keiser HR, Sjoerdsma A. Studies on β-aminopropionitrile in patients with scleroderma. Clin Pharmacol Ther 1967;8:593-602
17. Medsger TA Jr, Lucas M, Wildy KS, Baker C. D-penicillamine in systemic sclerosis? Yes! Scand J Rheumatol 2001;30:192-4